Effect of Long-Term Immunosuppressive Therapy on Soft Tissue and Bone Stability

Immunosuppressive drugs are essential for managing autoimmune diseases and preventing organ transplant rejection. However, their long-term use has significant adverse effects on various physiological systems, including the oral cavity. Immunosuppressive agents, particularly corticosteroids, cyclosporine, and mycophenolate mofetil, alter the oral microbiome, promoting the colonization of opportunistic pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. These microbial changes increase the risk of candidiasis, periodontitis, and gingival inflammation. Additionally, cyclosporine is strongly associated with gingival overgrowth, affecting approximately 30% of patients, with severe cases requiring surgical intervention. Beyond soft tissue effects, immunosuppressive therapy also compromises bone stability. Corticosteroids disrupt calcium metabolism, leading to decreased bone mineral density (BMD), increased fracture risk, and osteoporosis, particularly in the maxilla and mandible. The degree of bone loss correlates with dosage and duration of corticosteroid use, with trabecular bone being more susceptible than cortical bone. The reduction in BMD contributes to tooth loss and alveolar bone resorption, worsening oral health outcomes. Despite advancements in immunosuppressive therapy, effective strategies to mitigate its detrimental effects on oral tissues remain limited. Regular dental monitoring, dietary interventions rich in calcium and vitamin D, and personalized immunosuppressive regimens may help reduce oral complications. Further research is needed to develop targeted therapies that minimize immunosuppressive drug-induced damage while maintaining therapeutic efficacy. This review article explores the impact of immunosuppressive therapy on the stability of soft tissues and bone within the oral environment. It also highlights the importance of interdisciplinary collaboration between medical and dental professionals to ensure comprehensive care for patients undergoing long-term immunosuppressive therapy.